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Objective: A number of in vitro models of post-traumatic osteoarthritis (PTOA) have been developed to
study the effect of mechanical overload on the processes that regulate cartilage degeneration. While such
frameworks are critical for the identiﬁcation therapeutic targets, existing technologies are limited in
their throughput capacity. Here, we validate a test platform for high-throughput mechanical injury
incorporating engineered cartilage.
Method: We utilized a high-throughput mechanical testing platform to apply injurious compression
to engineered cartilage and determined their strain and strain rate dependent responses to injury. Next,
we validated this response by applying the same injury conditions to cartilage explants. Finally, we
conducted a pilot screen of putative PTOA therapeutic compounds.
Results: Engineered cartilage response to injury was strain dependent, with a 2-fold increase in
glycosaminoglycan (GAG) loss at 75% compared to 50% strain. Extensive cell death was observed adjacent
to ﬁssures, with membrane rupture corroborated by marked increases in lactate dehydrogenase (LDH)
release. Testing of established PTOA therapeutics showed that pan-caspase inhibitor [Z-VAD-FMK (ZVF)]
was effective at reducing cell death, while the amphiphilic polymer [Poloxamer 188 (P188)] and the free-
radical scavenger [N-Acetyl-L-cysteine (NAC)] reduced GAG loss as compared to injury alone.
Conclusions: The injury response in this engineered cartilage model replicated key features of the
response of cartilage explants, validating this system for application of physiologically relevant injurious
compression. This study establishes a novel tool for the discovery of mechanisms governing cartilage
injury, as well as a screening platform for the identiﬁcation of new molecules for the treatment of
PTOA.
© 2014 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
The primary function of articular cartilage is as a load-bearing
structure that supports and distributes the high stresses gener-
ated during normal physiological activities1. While cartilage
generally functions well over a lifetime of use, acute instances of.R. Dodge,McKayOrthopaedic
urgery, Perelman School of
all, 36th Street and Hamilton
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ed.upenn.edu (R.L. Mauck),
ternational. Published by Elsevier Lsupra-physiologic loading (e.g., accident or other traumatic event),
often result in tissue damage that initiates degenerative processes
within the joint. Indeed, a subset of osteoarthritis (OA), termed
post-traumatic osteoarthritis (PTOA) represents the signiﬁcant
fraction of patients who develop OA secondary to such joint
trauma. Based on the incidence of knee, hip, and ankle OA for pa-
tients with a history of joint injuries2, it is estimated that up to ~6
million individuals are burdened with PTOA in the US alone.
Cartilage pathology and PTOA incidence generally correlate with
the intensity of the original injury; patients with ligamentous or
meniscal injuries are 10-fold more likely, and those with articular
fractures are 20-fold more likely to develop knee OA compared to
individuals without previous joint injuries3,4. Despite a growing
understanding of the mechanical thresholds that instigate PTOA,td. All rights reserved.
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sion are not yet well understood.
To that end, a number of in vitro, ex vivo, and in vivo models of
cartilage injury have been developed to explore the temporal pat-
terns of anabolic and catabolic events that culminate in cartilage
degeneration. These models serve as useful platforms in which to
explore variables that regulate the extent of damage, including the
impact energy, peak stress/strain, and stress/strain rate. Common
markers of load-induced injury include tissue swelling and ﬁbril-
lation5, cell death at or near the injury site6,7, and increased
expression of proteases and inﬂammatory cytokines7,8. Biologic
mediators of PTOA act collectively to decrease chondrocyte matrix
biosynthesis5 and instigate a loss of proteoglycans and other matrix
elements5,6,9,10. Together, these molecular and compositional
changes culminate in a loss of tissue mechanical integrity5,7.
The timeline of activation of these degenerative processes (and
the controlling signaling mechanisms) is particularly important, as
the different stages of response post-injury may represent oppor-
tunities for therapeutic intervention11. Indeed, previous studies have
focused on small molecules targeting the early events, including
mechanisms that lead to cell death, release of inﬂammatory medi-
ators, and proteoglycan loss. Examples of such compounds include
pan-caspase inhibitors12,13 to decrease cell death, amphiphilic
surfactants14e16 to repair disrupted cell membranes, oxidative free-
radical scavengers13 to limit early inﬂammatory processes, as well as
growth factors17,18 and glucocorticoids19 to increase anabolic
response post-injury. In the above studies, these factors have shown
varied success in reducing cell death and matrix degradation in
in vitro and in vivomodels of PTOA, indicating that such early path-
ologic changes are appropriate targets for therapeutic intervention.
To date, the selection of agents that might abrogate PTOA
initiation has been based on their roles in canonical pathways
involved in cell physiology and/or OA progression. Since the
mechanisms of PTOA have not yet been fully elucidated, there may
be other agents not previously known to play a role in PTOA that
could have chondro-protective effects. In recent work, Sampson
et al. showed that parathyroid hormone (clinically used to improve
bone mass) administered to mice after meniscus destabilization
surgery was chondro-protective (or regenerative) in that it limited
hypertrophic changes after onset of instability20. Wang et al. also
showed that the inﬂammatory complement system regulated
cartilage degradation in mouse models of joint instability21. These
studies illustrate the signiﬁcant role that such non-canonical
pathways may play in mediating the degenerative response in
situations of chronic overload; the acute injury response may
similarly initiate heretofore unexplored signaling pathways.
High-throughput (HT) screening enables the rapid evaluation of
small molecule libraries for the discovery of novel compounds
relevant to tissue development and healing without prior knowl-
edge of the mechanism of action. Recently, Johnson et al. developed
an image-based high-throughput screening system to identify
molecules that promoted chondrogenic differentiation of mesen-
chymal stem cells (MSCs)22. From the 1000s of molecules screened
in that study, several “hits” were identiﬁed, with the small mole-
cule kartogenin emerging as the most promising. Follow-up sec-
ondary in vitro assays (e.g., Real-Time Polymerase Chain Reaction
(RT-PCR)) and tertiary in vivo investigations (rodent joint instability
models) illustrated that kartogenin also had a chondro-protective
effect and acted by disrupting the binding of a speciﬁc transcrip-
tion factor subunit to an actin associated protein. Given the non-
intuitive mechanism of action, this study highlights the need for
unbiased screening tools to guide molecular discovery speciﬁc to a
particular disease process.
To enable such screens in the context of PTOA, we developed a
high-throughput in vitro mechanical injury platform that iscompatible with drug screening. While in vitro models of injury
using explants have been valuable in elucidating regional changes
in cell viability and matrix loss, explants are not ideal for high-
throughput screening due to the large number of samples required
and variation in the cellular and molecular stratiﬁcations found
throughout the joint. Cartilage tissue engineering, which aims to
mimic the biochemical and mechanical properties of native carti-
lage for joint repair, can generate cartilage-like analogs with which
to study the pathogenesis of PTOA. Engineered cartilage can also
be fabricated in a uniform manner and in large quantity, and as
such are ideal for high-throughput screening applications. In
particular, we have studied a scaffold-less method to generate
cartilage tissue analogs (CTAs) that closely mimic native cartilage
both in terms of extracellular matrix composition and biome-
chanical properties23e25.
Here, we adapted our high-throughput mechanical testing sys-
tem26 to apply compressive injury to CTAs in a rapid and repro-
ducible manner. The primary goals of this study were to determine
the strain and rate dependent response of engineered cartilage to
compressive injury, to evaluate the progression of degeneration,
and to validate this response with respect to native articular
cartilage explants treated similarly. Our ﬁndings validate the use of
engineered cartilage as a surrogate for studying mechanisms of
PTOA pathogenesis and introduce a new screening tool with which
to identify novel compounds that can attenuate degeneration
following cartilage injury.
Methods
Fabrication of cartilage tissue analogs
Engineered CTAs were produced as described previously24,25.
Brieﬂy, articular cartilagewas harvested from juvenile bovine knees
(2e6 months old, Research 87, MA), ﬁnely minced, and digested
overnight (12e16 h) in Dulbecco's Modiﬁed Eagle Medium (DMEM)
containing collagenase Type II (298 U/mL Worthington, NJ). Tissue
digests were ﬁltered (70 mm pore mesh), washed with PBS con-
taining 200 U/mL penicillin, 200 mg/mL streptomycin, 5 mg/mL
Fungizone (PSF, Life Technologies, NY), and centrifuged at 1750 rpm
for 15 min at 12C (3) until collected into a single suspension.
Chondrocytes were resuspended at 5  106 cells/mL in complete
medium (high glucose DMEM containing 10% Fetal Bovine Serum
(FBS), 100 U/mL penicillin, 100 mg/mL streptomycin, 2.5 mg/mL
Fungizone, 1% MEM Vitamin Solution (Gibco), 25 mMHEPES buffer,
50 mg/mL ascorbic acid25). This cell suspension was plated into
ultra-lowadhesion (polyHEMA coated) 96 well plates (Corning, NY)
at 1  106 cells/well, where chondrocytes coalesced within 24 h to
form a CTA25. CTAs were cultured for a minimum of 14e16 weeks in
complete medium prior to injury.
Injurious compression of CTAs and native tissue explants
To determine the level of injury necessary to induce pathological
changes in CTAs that mimic changes in cartilage explants, four
different injurious compression protocols were applied in a single-
sample manner based on previously established injury parame-
ters5,6,8. CTAs were subjected to either 50% or 75% strain at one of
two strain rates, 10% strain/s or 50% strain/s, followed by a hold
period for a total ramp-hold compression time of 10 s. Constructs
were then cultured for 5 days after injury, and both CTAs and media
were harvested at 12, 24, and 120 hours post-injury for evaluation of
biochemical content and presence of soluble catabolic markers as
described below. Based on the outcomes of single-sample injury,
high-throughput injury was applied to constructs at 75% strain at
50% strain/s. For this, a custom high-throughput mechanical
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housing with linear bearings to guide the vertical displacement of a
loading platen which included a force-sensitive resistor (FSR) array
for real-time monitoring of compressive forces during injury. In the
current version of the device, 48 samples are housed in a standard
48-well plate and are compressed via Polytetraﬂuoroethylene (PTFE)
indenters, with load recorded continuously during injury using an
NI-DAQ board (National Instruments, USB-2665) and a custom
Labview program (National Instruments, V8.6) with post-processing
in MATLAB (Mathworks, R2012a). Injurious strain and strain rate
were calculated based on the average height of constructs. After
injury, constructswere cultured for 5 dayswith sample harvest at 24,
48, and 120 h post-injury. As a positive control, constructs were
treated with IL-1b (10 ng/mL) for 5 days27e29. To validate the injury
response in CTAs, cartilage explants were injured in a similar
manner. Full-thickness articular cartilage (chondral only) explants
(4 mm diameter) were harvested from the trochlear groove of ju-
venile bovine knees and trimmed to 3e4mm thickness, keeping the
superﬁcial layer intact. Cartilage cylinders were subjected to 75%
strain at 50% strain/s using a single-sample injury protocol matching
the high-throughput injury of the CTAs. Cartilage cylinders were
cultured for 5 days and evaluated as above in order to make com-
parisons between native and engineered cartilage response to injury.
Treatment with putative therapeutic PTOA compounds
In a subset of studies, and immediately following injury at 75%
strain applied at 50%/swith thehigh-throughput device, engineered
cartilage was treated with one of the three following agents: (1) N-
Acetyl-L-Cysteine (NAC, 2mm, Sigma,MO) a reactive oxygen species
scavenger, (2) Z-VAD-FMK (ZVF, 100 mM, Promega, WI) a pan-
caspase inhibitor, or (3) Poloxamer 188 (P188, 8 mg/mL, Corning,
NY), an amphiphilic polymer capable of inserting into the cell
membrane. Each compoundwas included in the culturemedium for
the initial 48 h post-injury at levels previously reported to have
beneﬁcial effects in the context of cartilage injury12e15. Harvest time
points and outcome measures were the same as described above.
Biochemical and molecular evaluation of injury response
Following injury, construct wet weight and dry weight
(following lyophilization) were determined. Samples were then
papain digested and glycosaminoglycan (GAG) content determined
using the dimethylmethylene blue assay, with chondroitin-6-
sulfate as a standard, as previously described30. DNA per
construct was measured using the PicoGreen assay (Life Technol-
ogies, NY). Matrix content was measured per construct or
normalized to DNA, and swelling ratio was calculated as the ratio of
wet to dry weight at the time of harvest. Mediumwas assayed at all
harvest time points for GAG release and lactate dehydrogenase
activity (LDH; CytoTox-ONE Homogeneous Membrane Integrity
Assay, Promega, WI), which is released upon disruption of the cell
membrane and is a measure of cell injury.
Histological analysis of injury response
For viability analysis, constructs were stained using the Live/
Dead staining kit (Live/Dead Viability/Cytotoxicity Kit, Life Tech-
nologies, NY) and imaged on a Nikon Eclipse TE2000-U (excitation
wavelengths: Live: 420e495 nm and Dead: 532e587 nm) using 2
or 10 objectives. Additional samples were ﬁxed in 4% para-
formaldehyde (Affymetrix, CA), dehydrated, embedded in parafﬁn,
and sectioned to 8 mm thickness. Sections were stained for pro-
teoglycan distribution with Alcian Blue (Rowley Biochemical
Institute, MA) as previously described31.Statistical analysis
Effect of strain and strain rate for single-sample injury, differ-
ential effects of injury or IL-1b as a function of time, and compar-
isons to chondral explants were assessed by two-way analysis of
variance (ANOVA) with Bonferroni's post-hoc test (P < 0.05). PTOA
compound effects were compared to injury alone using a single-
sample t-test (P < 0.05). All statistical analyses were conducted
using the SYSTAT13 software (v.13.00.05, San Jose, CA).
Results
Effect of strain magnitude and strain rate on CTA injury response
CTAswere injured in a single-samplemanner, with compression
to 50% or 75% strain at 10% or 50% strain/s. Representative stress vs
time proﬁles of injured CTAs showed that both strain and strain rate
signiﬁcantly increased peak stress (with values reaching 1e2 MPa)
(Fig. 1). Interestingly, compression of CTAs up to 75% strain resulted
in multiple peaks, likely indicative of construct fracture and re-
compression during loading. Construct failure at high strains was
conﬁrmed by histological analysis. At 50% strain, there was internal
ﬁssuring of the construct and focal areas of GAG loss [Fig. 2(G)]. At
the higher 75% strain level, there was obvious surface ﬁbrillation,
loss of construct shape, and widespread GAG depletion [Fig. 2(H)].
In comparison, control constructs maintained uniform GAG distri-
bution throughout the construct [Fig. 2(F)]. Rapid application of
50% strain resulted in cell death throughout the intact construct
thickness, while 75% strain primarily resulted in cell death in areas
adjacent to ﬁssures [Fig. 2(CeE)]. GAG within the construct and
released to the medium was measured 0e12, 0e24, and 24e120 h
post-injury. 75% strain applied at either strain rate reduced GAG/
DNA in constructs for all time points post-injury [Fig. 2(A)].
Furthermore, injury at both 50% and 75% strain signiﬁcantly
increased GAG released to the medium compared to un-injured
controls. Application of 75% strain resulted in an ~2-fold greater
increase in GAG release compared to 50% strain applied at the same
rate [Fig. 2(B)].
High-throughput injury of engineered cartilage
Based upon the outcomes of single-sample injury of CTAs, 75%
strain applied at 50% strain/s was chosen for the high-throughput
application of compressive injury. Injury was carried out using the
custom high-throughput mechanical injury device, shown in
Fig. 3(A). While CTAs had slight variations in height due to their free
form assembly and growth during pre-culture, an applied target
strain of 75% resulted in applied strains ranging from 59% to 99% in
individual CTAs, with a mean strain of 78 ± 10% for a full 48-well
plate of constructs [Fig. 3(B)]. Simultaneous compression resulted
in peak loads in CTAs comparable to single-sample compression; a
3D graphical representation of the real-time peak voltages (peak
load) is provided in Fig. 3(C), showing similarity across constructs.
GAG released from high-throughput constructs was ~2e3-fold
higher than un-injured controls for all time points [Fig. 4(A)], a
response similar to that evoked by the single-sample injury.
Interestingly, while IL-1 treatment initially caused GAG release at a
similar magnitude as injury, by 120 h of continuous treatment, GAG
release was ~9-fold higher than un-injured controls and 4e5-fold
greater than injured samples. Evaluation of LDH in the medium
indicated that injury resulted in dramatic loss in viability over the
short term [Fig. 4(B)]. Conversely, IL-1 treatment did not disrupt
membrane integrity and so resulted in little LDH release relative to
baseline levels. Tissue swelling was calculated as a measure of
degeneration, as swelling is observed clinically in early stages of
Fig. 1. Injurious compression protocol. (A, B) Engineering strain and stress proﬁles of
CTAs for the four injury protocols tested: 50% or 75% strain applied at either 10% or 50%
strain/s for a total compression time (ramp and hold) of 10 s. Proﬁles are representative
of constructs injured in that group (N ¼ 24/group, all CTAs fabricated with pooled
chondrocytes of a single animal). (C) Strain and strain rate both signiﬁcantly inﬂuence
peak stress, with 75% strain applied at 50% strain/s yielding the highest peak stress.
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control constructs did not change [Fig. 4(C)]. In contrast, treatment
with IL-1 only affected swelling after 5 days due to continued
matrix degradation.
Validation of engineered cartilage as an analog for injury of native
tissue
To validate the injury response of CTAs, explants were subjected
to the same injury protocol and outcomes. A representative peakstress proﬁle for a cartilage explant shows multiple peaks, similar
to that observed with the engineered cartilage, with the ﬁrst peak
concurrent with gross tissue failure, followed by a second or third
peak due to the further compression of the fragments [Fig. 5(A),
inset]. The ﬁrst peak in stress occurred at ~16 MPa for cartilage
explants, similar to previously reported values for explants subject
to injurious compression at high strains or strain rates5,32. GAG
release from explants and CTAs 24 h post-injury showed similar
loss in matrix content per construct [Fig. 5(A)]. Similarly, LDH
release showed comparable ﬁndings, with injured CTAs and ex-
plants both showing evidence of cell membrane damage compared
to un-injured controls, though LDH release from explants was ~2-
fold greater than from CTAs [Fig. 5(B)].
Response of engineered cartilage to putative PTOA therapeutic
compounds
As a secondary validation of this high-throughput injury system,
we subsequently screened several putative therapeutic PTOA
compounds. In the initial 24 h, ZVF treatment signiﬁcantly reduced
LDH release by 20% compared to injury alone; however NAC and
P188 did not alter membrane disruption [Fig. 6(A)]. By 120 h post-
injury, however, both NAC and P188 decreased GAG loss (by 18%
and 20% respectively) compared to injury alone, although neither
agent restored GAG content to control levels [Fig. 6(B)]. Despite
increasing initial cell viability after injury, ZVF treatment did not
alter GAG content in injured samples.
Discussion
Traumatic joint injury initiates a cascade of catabolic and
anabolic processes, the imbalance of which often results in further
cartilage degeneration. However, the pathways that underlie these
irreversible changes remain poorly understood. As such, in order to
conduct an efﬁcient and unbiased evaluation of molecules that may
modulate PTOA biologic processes, high-throughput screening
would be a valuable tool to evaluate compound libraries after
injury. In this study, we utilized engineered cartilage analogs (CTAs)
in conjunction with a high-throughput mechanical injury device to
develop a platform for studying PTOA pathology and to enable the
discovery of potential therapeutics.
Primary markers of cartilage damage following traumatic injury
include matrix disruptions, GAG loss from the matrix, and cell
death. Using CTAs as an in vitro cartilage surrogate for studying
PTOA, our objectivewas to deﬁne the thresholds for inducing such a
response, to determine the uniformity of response using a high-
throughput device, and to benchmark the response against that of
native cartilage. To deﬁne thresholds for injury, single-sample
compressionwas applied to constructs at strains (50% and 75%) and
strain rates (10% and 50% strain/s) previously explored5,6,8. In ex-
plants, while strains larger than 50% cause permanent deformation
and surface ﬁbrillation (stresses >15 MPa), strains greater than 80%
(stresses >20 MPa) cause deep ﬁbrillation and complete destruc-
tion of matrix integrity32. In CTAs cultured for up to 16 weeks,
whose properties approach that of native tissue25, application of
75% strain resulted in widespread ﬁssuring, with a 2-fold increase
in release of GAG to the medium compared to 50% strain. The
greater release of GAG observed at this higher strain may be due to
the increased surface area for diffusion. DiMicco et al. observed
with injury of osteochondral explants an initially high rate of GAG
release not blocked by Matrix Metalloproteinase (MMP) or
biosynthesis inhibitors, indicating that this early release (4 days
post-injury) likely consisted of diffusion of larger proteoglycan
molecules out of the tissue rather than enzymatically-cleaved
fragments, as is observed at later time points9.
Fig. 2. Effect of strain and strain rate on matrix retention and loss following injury. (A) GAG content normalized to DNA content within CTAs (N ¼ 3/group, all CTAs fabricated with
pooled chondrocytes of a single animal) showed consistent loss of matrix following injury applied to 75% strain at 50% strain/s. (B) GAG released to the medium (N ¼ 3/group, all
CTAs fabricated with pooled chondrocytes of a single animal) mirrored that of the construct, but with signiﬁcant loss observed in a strain-dependent manner at both 50% and 75%
strain, regardless of the strain rate during injury. (CeE) Live/Dead staining (green: viable; red: non-viable) 24 h post-injury for the highest strain rate illustrated that 50% strain
resulted in focal regions of cell death with internal ﬁssuring while control constructs contained viable cells throughout. 75% strain caused more extensive cell death superﬁcially and
adjacent to large and full-depth ﬁssures (N ¼ 2/group). (DeF) Alcian blue staining for proteoglycans showed control constructs with well distributed matrix, that 50% strain caused
internal ﬁssuring with local matrix loss (black arrows), and that 75% strain caused widespread matrix damage with fainter staining for proteoglycans throughout the construct
(N ¼ 2/group). *P vs control and #P vs 50% strain for a respective time point; P < 0.001 for * and # symbols alone.
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observed adjacent to surface ﬁssures and internal cavities. In
cartilage explant studies, the extent and depth of cell death has
been reported to be both strain and strain rate dependent6,7,33,34. In
addition, similar to our observations, extensive loss of cell viability
occurs along ﬁssure lines/regions both in whole joint35 and osteo-
chondral explant6,36 models with cell viability increasing withFig. 3. High throughput mechanical screening (HTMS) device for applying compressive inju
bearings to guide the vertical motion of the sensor loading platen. The sensor adhered to
consisting of PTFE indenters aligned with a standard 48-well plate containing engineered co
compression of 75% strain at 50% strain/s applied to constructs. (B) Example distribution of s
78 ± 10% strain for the population. (C) Peak voltage recordings in each well showed the undistance from the ﬁssure line. However, with time, cell death ex-
pands to these non-ﬁssure regions, which may suggest two
mechanisms by which cell viability decreases with injury. Under
high loading rates, cells may not be able to “recruit” sufﬁcient
membrane components in order to deform under compression, and
in areas of cartilagewith ﬁssuring, cells may experience high strains
and so rupture37. The expansion of the region of cell death to non-ries to CTAs. (A) The HTMS injury device consisted of an aluminum frame with linear
the underside of the loading platen comes into contact with a well plate assembly
nstructs. Average sample height was measured prior to testing, with a target injurious
ample heights and applied strains for each construct (N ¼ 48/plate). Average strain was
iformity of peak load responses in engineered cartilage during compressive injury.
Fig. 4. Release of ECM and cellular enzymes and alterations in CTA properties following
high-throughput mechanical injury. (A) Injury of engineered cartilage signiﬁcantly
increased GAG release to themedium in amanner similar to that of IL-1 treatment alone
for the ﬁrst 48 h; after 48 h, IL-1 causes a 4e5-fold higher level of GAG release from the
construct compared to injury alone (N ¼ 8 media collections per sample combined into
4 aliquots, Sol-GAG is an average value per aliquot/group). (B) LDH release (a measure of
cell viability) indicated that injury caused a large increase in chondrocyte membrane
disruption in the ﬁrst 24 h after injury, while IL-1 resulted in little membrane damage
with continuous exposure for 5 days (N¼ 8media collections per sample combined into
4 aliquots/group, LDH is an average value per aliquot). (C) The swelling ratio (calculated
as the ratio of wet to dry weight) indicated that injury caused gross tissue damage and
swelling within 24 h post-injury. In contrast, IL-1 treatment resulted in increased
swelling only after 120 h of treatment (N ¼ 4 samples/group; all CTAs fabricated with
pooled chondrocytes of a single animal). *P vs control and #P vs IL-1 for a respective time
point; P < 0.001 for * and # symbols alone.
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factors that induce apoptosis and contribute to the propagation of
the injury response35,36,38.
Upon determining that 75% strain at 50% strain/s induced a
degenerative response in CTAs, we next used our high-throughput
device to apply consistent compressive injury to up to 48 samples
simultaneously. While there were small variations in applied strain
due to differences in construct height, the response was sufﬁciently
uniform so as to provoke a ~2e3-fold increase in GAG release
compared to un-injured controls, comparable to the single-sample
response. Monitoring LDH release as a quantitative measure of cell
death similarly conﬁrmed that cell membrane damage is a repeat-
able effect of compressive injury in this engineered model of PTOA.
We subsequently validated the CTA response against that of
native cartilage. Peak stresses during compressive injury of native
tissuewere ~20-fold higher than CTAs. This difference could explain
the 2-fold greater increase in LDH release as compared to CTAs in the
ﬁrst 24 h. Indeed, strain rate and peak stress dependent increases in
LDHrelease have beenobserved in cartilage explants39,40. Additional
factors which may also inﬂuence the extent of cell death include
matrix composition and organization41. In our study, GAG release
was comparable between explants and CTAs, with a 4-fold increase
in GAG release to the medium compared to un-injured controls
within the ﬁrst 24 h. Previouswork has similarly reported an ~2-fold
increase in GAG release in the ﬁrst 24 h from explants subjected to
injury at fracture levels (e.g., 50% strain at 100% strain/s9,10 or high
strain rates of 50%or 70% strain/s6). Given that theCTAcanbe injured
at any point in its maturation, from the cell-rich, matrix-poor more
fetal-like state, through to the mature, matrix-rich, cell poor adult-
like state25, a range of studies may be performed to determine
how injury and tissue maturation state interact.
Using our CTAs, we observed a consistent and marked effect of
load-induced injury; however, in PTOA, degeneration is also
potentiated by the presence of inﬂammatory cytokines, such as IL-
1b, which may differentially govern the chondrocyte response in
our in vitro system. While mechanical injury caused extensive cell
membrane damage asmeasured by LDH release, IL-1 had aminimal
effect. In contrast, while IL-1 and injury initially increased GAG
release to similar levels, by 120 h of exposure to IL-1, GAG release
was 3-fold higher than injury alone. IL-1 is known to cause matrix
degradation via increased nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-kB) activation, expression of
proteases (e.g., MMP and A Disintegrin AndMetalloproteinase with
Thrombospondin Motifs (ADAMTS)), and other pro-inﬂammatory
molecules (e.g., NO and Cyclooxygenase-2 (COX-2))42,43. Such
temporal patterns of matrix disruption may also explainwhy injury
caused rapid construct swelling (mechanical disruption of the
nascent collagen network), while this swelling response took
longer with IL-1 mediated degradation (sustained enzymatic
cleavage). These observations are consistent with reports of injury-
induced increases in water content of explants in a strain-depen-
dent manner5,32, as well as of chondrocyte-seeded agarose hydro-
gels following a crush injury41.
Finally to determine whether this CTA model is useful for
screening new PTOA therapeutics in a high-throughput manner,
bioactive molecules previously reported to reduce cell death and
proteoglycan loss post-injury were evaluated. Application of these
compounds to CTAs resulted in early protection against loss of
viability (ZVF) and late protection against matrix loss (P188 and
NAC) after injury. ZVF has been observed to increase cell viability by
15e20% with 48 h of treatment following compression of explants
(30% strain at 0.6 s1; see Ref. 12 or impact at 7 J/cm2; see Ref. 13).
Although NAC has likewise been shown to increase viability by
~30% following injury13, here we found no effect on reducing
membrane damage. However, NAC was effective at reducing GAG
Fig. 5. Comparison of native and engineered cartilage injury response. Bovine cartilage explants were compressed to 75% strain at 50%/s. (A-inset) Representative peak stress proﬁle
of explants during injurious compression showing a ﬁrst peak concurrent with gross tissue failure, followed by a second peak resulting from further compression of the fragments.
Average ﬁrst peak stress was 16.8 ± 4.3 MPa (N ¼ 12, all explants harvested from a single animal). Soluble factors released to the medium in the ﬁrst 24 h showed that (A) GAG
release was comparable between injured explants and CTAs and was signiﬁcantly greater than un-injured samples (N ¼ 4 for explants, and N ¼ 8 media collections per sample
combined into 4 aliquots/group). (B) In contrast, LDH release was approximately 2-fold greater in explants compared to CTAs following injury (N ¼ 4 for explants, and N ¼ 8 media
collections per sample combined into 4 aliquots/group). P < 0.001 for * vs control within tissue type and # vs CTAs.
B. Mohanraj et al. / Osteoarthritis and Cartilage 22 (2014) 1282e12901288loss, consistent with observations of a ~20% reduction in GAG loss
from chondral explants following injury (7 J/cm2; see Ref. 13).
While our ﬁndings also showed that P188 improved GAG retention,
literature ﬁndings have been variable, with some studies noting a
~20% increase in cell viability14 withminimal changes in GAG loss15.
One possible explanation is that P188 insertion into the membrane
may prevent the expulsion of intracellular contents which in
turn may preserve local ion concentration gradients44 to allowFig. 6. Effect of putative PTOA therapeutics on matrix content and cell death after
injury. (A) LDH release 24 h post-injury was reduced by ~30% with ZVF treatment
while NAC and P188 had no effect compared to injury alone (N ¼ 8 media collections
per sample combined into 4 aliquots/group). (B) GAG content in the construct
120 h post-injury showed that NAC and P188 treatment resulted in retention of ~20%
more GAG compared to injury alone (N ¼ 4/group). Dashed red line demarcates results
from two separate experiments (CTAs for each experiment fabricated with pooled
chondrocytes of a single animal) evaluating the effects of NAC, ZVF, and P188.living cells to function normally. It is important to note that
although these compounds did have acute effects on matrix
retention and cell viability, none were able to return constructs to
control levels, highlighting the importance of continuing thera-
peutic discovery.
Taken together, these studies illustrate that injurious compres-
sion of CTAs replicates key markers of the injury response in native
cartilage explants, validating this approach as a model system for
studying the processes that govern cartilage degeneration in PTOA.
While our current model focuses on mimicking articular fracture,
this system can be adapted for applying insults that do not produce
structural damage to mimic subtle injury scenarios and also for
cyclic overloading injuries. In addition, our testing platform, along
with the ability to form large numbers of these cartilage analogs in
a micro-scale format, sets the stage for high-throughput screening
of large chemical libraries to more rapidly identify therapeutics to
attenuate progressive degenerative joint changes after injury.
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